

PHARMACY PRIOR AUTHORIZATION REQUEST FORM
ZOLGENSMA®

For authorization, please answer each question and fax this form PLUS chart notes back to the U of U Health Plans Prior Authorization Department at 888-509-8142.

Failure to submit clinical documentation to support this request will result in a dismissal of the request.

If you have prior authorization questions, please call for assistance: University of Utah Health Employees: 855-856-5690, Individual & Family Plans : 855-869-4769, Commercial Groups: 855-859-4892, MHC 855-885-7695

Disclaimer: Prior authorization request forms are subject to change in accordance with Federal and State notice requirements.

Date:	Member Name:	ID#:
DOB:	Gender:	Physician:
Office Phone:	Office Fax:	Office Contact:
Height/Weight:	HCPCS Code:	

Member must try formulary preferred drugs before a request for a non-preferred drug may be considered. If treatment with preferred products has not been successful, you must submit which preferred products have been tried, dates of treatment, and reason for failure. Reasons for failure must meet the Health Plan medical necessity criteria.

Product being requested: Zolgensma® (onasemnogene abeparvovec-xioi)

Dosing/Frequency: _____

If the request is for reauthorization, proceed to reauthorization section.

Questions	Yes	No	Comments/Notes
1. Does the member have a genetically confirmed diagnosis of spinal muscular atrophy (SMA) with bi-allelic mutations in the survival motor neuron 1 (SMN1) gene and ≤ 3 copies of SMN2?	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation
2. Is the medication prescribed by or in consultation with a physician who specializes in the treatment of SMA?	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation
3. Will the member be less than 2 years of age at the time of administration?	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation
4. Is the member's weight ≤13.5 kg?	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation
5. Does the member have advanced SMA with any of the following: <ul style="list-style-type: none"> • Complete paralysis of limbs • Invasive ventilator support (tracheostomy) 	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation
6. Does documentation provide anti-AAV9 antibody titer ≤1:50 as determined by Enzyme-linked Immunosorbent Assay (ELISA) Binding immunoassay?	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation
7. Was the member born prematurely?	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation
8. Has the member received Zolgensma® before?	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation

9. Is the member currently receiving routine concomitant SMN modifying therapy, e.g., Spinraza® (nusinersen), Evrysdi® (risdiplam)?	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation
What medications and/or treatment modalities have been tried in the past for this condition? Please document name of treatment, reason for failure, treatment dates, etc.			
Additional information:			
Physician Signature:			

**** Failure to submit clinical documentation to support this request will result in a dismissal of the request.****

Policy PHARM- M012
 Origination Date: 10/01/2019
 Reviewed/Revised Date: 10/26/2022
 Next Review Date: 10/26/2023
 Current Effective Date: 11/01/2022

Confidentiality Notice

This document and any accompanying document contain confidential information and is intended for the use of the individual or entity named on this transmission sheet. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or the taking of any action in reliance on the contents of this information is strictly prohibited and the document should be returned to this office immediately. If you have received this facsimile in error, please notify us by telephone immediately and destroy document received.